# enGene Therapeutics Inc.: financial statements, quarterly

ENGN · Nasdaq · CIK 1980845 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Oct 31

Pages: [Overview](/companies/engn.md) · [Financials](/companies/engn/financials.md) · [Filings](/companies/engn/filings.md) · [Insiders](/companies/engn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/engn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-10-31) | Q1 FY2024 (2024-01-31) | Q2 FY2024 (2024-04-30) | Q3 FY2024 (2024-07-31) | Q4 FY2024 (2024-10-31) | Q1 FY2025 (2025-01-31) | Q2 FY2025 (2025-04-30) | Q3 FY2025 (2025-07-31) | Q4 FY2025 (2025-10-31) | Q1 FY2026 (2026-01-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [5.7 d](/filings/0000950170-24-138472.md) | [5.6](/filings/0000950170-25-036281.md) | [9.9](/filings/0000950170-25-085143.md) | [11.5](/filings/0000950170-25-114224.md) | [11.3 d](/filings/0001193125-25-328743.md) | [20.0](/filings/0001193125-26-097541.md) | [20.2](/filings/0001193125-26-270386.md) | [22.6](/filings/0001193125-26-384383.md) | [31.7 d](/filings/0001193125-25-328743.md) | [22.3](/filings/0001193125-26-097541.md) | [22.2](/filings/0001193125-26-270386.md) | [20.1](/filings/0001193125-26-384383.md) |
| Operating income | $m | [(10.4) d](/filings/0000950170-24-138472.md) | [(10.8)](/filings/0000950170-25-036281.md) | [(17.3)](/filings/0000950170-25-085143.md) | [(16.8)](/filings/0000950170-25-114224.md) | [(17.5) d](/filings/0001193125-25-328743.md) | [(26.6)](/filings/0001193125-26-097541.md) | [(27.1)](/filings/0001193125-26-270386.md) | [(29.9)](/filings/0001193125-26-384383.md) | [(39.5) d](/filings/0001193125-25-328743.md) | [(31.2)](/filings/0001193125-26-097541.md) | [(32.0)](/filings/0001193125-26-270386.md) | [(34.0)](/filings/0001193125-26-384383.md) |
| Interest expense | $m | [1.2 d](/filings/0000950170-24-008125.md) | [0.6](/filings/0000950170-24-029413.md) | [0.7](/filings/0000950170-24-073330.md) | [0.8](/filings/0000950170-25-114224.md) | [0.8 d](/filings/0001193125-25-328743.md) | [0.8](/filings/0001193125-26-097541.md) | [0.7](/filings/0001193125-26-270386.md) | [0.8](/filings/0001193125-26-384383.md) | [0.8 d](/filings/0001193125-25-328743.md) | [0.7](/filings/0001193125-26-097541.md) | [0.7](/filings/0001193125-26-270386.md) | [0.8](/filings/0001193125-26-384383.md) |
| Income tax | $m | [0.0 d](/filings/0000950170-24-138472.md) | [(0.0)](/filings/0000950170-25-036281.md) | [0.0](/filings/0000950170-25-085143.md) | [(0.0)](/filings/0000950170-25-114224.md) | [0.0 d](/filings/0001193125-25-328743.md) | [0.0](/filings/0001193125-26-097541.md) | [0.2](/filings/0001193125-26-270386.md) | [0.2](/filings/0001193125-26-384383.md) | [(0.5) d](/filings/0001193125-25-328743.md) | [0.0](/filings/0001193125-26-097541.md) | [0.0](/filings/0001193125-26-270386.md) | [0.0](/filings/0001193125-26-384383.md) |
| Net income | $m | [(82.5) d](/filings/0000950170-24-138472.md) | [(10.7)](/filings/0000950170-25-114224.md) | [(15.0)](/filings/0000950170-25-114224.md) | [(14.1)](/filings/0000950170-25-114224.md) | [(15.3) d](/filings/0001193125-25-328743.md) | [(24.6)](/filings/0001193125-26-384383.md) | [(25.8)](/filings/0001193125-26-384383.md) | [(29.0)](/filings/0001193125-26-384383.md) | [(37.9) d](/filings/0001193125-25-328743.md) | [(29.8)](/filings/0001193125-26-384383.md) | [(30.2)](/filings/0001193125-26-384383.md) | [(32.5)](/filings/0001193125-26-384383.md) |
| Diluted EPS | $ per share | not reported | [0.46](/filings/0000950170-25-036281.md) | [0.38](/filings/0000950170-25-085143.md) | [0.32](/filings/0000950170-25-114224.md) | not reported | [0.48](/filings/0001193125-26-097541.md) | [(0.51)](/filings/0001193125-26-270386.md) | [(0.57)](/filings/0001193125-26-384383.md) | not reported | [0.44](/filings/0001193125-26-097541.md) | [(0.43)](/filings/0001193125-26-270386.md) | [(0.47)](/filings/0001193125-26-384383.md) |
| Basic EPS | $ per share | not reported | [0.46](/filings/0000950170-25-036281.md) | [0.38](/filings/0000950170-25-085143.md) | [0.32](/filings/0000950170-25-114224.md) | not reported | [0.48](/filings/0001193125-26-097541.md) | [(0.51)](/filings/0001193125-26-270386.md) | [(0.57)](/filings/0001193125-26-384383.md) | not reported | [0.44](/filings/0001193125-26-097541.md) | [(0.43)](/filings/0001193125-26-270386.md) | [(0.47)](/filings/0001193125-26-384383.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-10-31) | Q1 FY2024 (2024-01-31) | Q2 FY2024 (2024-04-30) | Q3 FY2024 (2024-07-31) | FY2024 (2024-10-31) | Q1 FY2025 (2025-01-31) | Q2 FY2025 (2025-04-30) | Q3 FY2025 (2025-07-31) | FY2025 (2025-10-31) | Q1 FY2026 (2026-01-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [81.5](/filings/0000950170-24-138472.md) | [85.6](/filings/0000950170-24-029413.md) | [265](/filings/0000950170-24-073330.md) | [258](/filings/0000950170-24-105180.md) | [173](/filings/0001193125-25-328743.md) | [62.3](/filings/0000950170-25-036281.md) | [57.5](/filings/0000950170-25-085143.md) | [32.6](/filings/0000950170-25-114224.md) | [50.2](/filings/0001193125-26-384383.md) | [36.6](/filings/0001193125-26-097541.md) | [29.8](/filings/0001193125-26-270386.md) | [41.0](/filings/0001193125-26-384383.md) |
| Current assets | $m | [85.4](/filings/0000950170-24-138472.md) | [89.6](/filings/0000950170-24-029413.md) | [270](/filings/0000950170-24-073330.md) | [263](/filings/0000950170-24-105180.md) | [247](/filings/0001193125-25-328743.md) | [222](/filings/0000950170-25-036281.md) | [228](/filings/0000950170-25-085143.md) | [211](/filings/0000950170-25-114224.md) | [201](/filings/0001193125-26-384383.md) | [289](/filings/0001193125-26-097541.md) | [270](/filings/0001193125-26-270386.md) | [278](/filings/0001193125-26-384383.md) |
| Total assets | $m | [87.0](/filings/0000950170-24-138472.md) | [93.4](/filings/0000950170-24-029413.md) | [274](/filings/0000950170-24-073330.md) | [267](/filings/0000950170-24-105180.md) | [311](/filings/0001193125-25-328743.md) | [286](/filings/0000950170-25-036281.md) | [267](/filings/0000950170-25-085143.md) | [246](/filings/0000950170-25-114224.md) | [221](/filings/0001193125-26-384383.md) | [337](/filings/0001193125-26-097541.md) | [308](/filings/0001193125-26-270386.md) | [288](/filings/0001193125-26-384383.md) |
| Current liabilities | $m | [5.3](/filings/0000950170-24-138472.md) | [6.9](/filings/0000950170-24-029413.md) | [6.3](/filings/0000950170-24-073330.md) | [13.5](/filings/0000950170-24-105180.md) | [14.7](/filings/0001193125-25-328743.md) | [13.0](/filings/0000950170-25-036281.md) | [18.0](/filings/0000950170-25-085143.md) | [20.4](/filings/0000950170-25-114224.md) | [32.0](/filings/0001193125-26-384383.md) | [24.6](/filings/0001193125-26-097541.md) | [21.5](/filings/0001193125-26-270386.md) | [27.2](/filings/0001193125-26-384383.md) |
| Total liabilities | $m | [14.5](/filings/0000950170-24-138472.md) | [31.0](/filings/0000950170-24-029413.md) | [30.6](/filings/0000950170-24-073330.md) | [36.6](/filings/0000950170-24-105180.md) | [38.6](/filings/0001193125-25-328743.md) | [36.0](/filings/0000950170-25-036281.md) | [39.4](/filings/0000950170-25-085143.md) | [44.9](/filings/0000950170-25-114224.md) | [53.8](/filings/0001193125-26-384383.md) | [55.6](/filings/0001193125-26-097541.md) | [52.4](/filings/0001193125-26-270386.md) | [58.0](/filings/0001193125-26-384383.md) |
| Shareholders' equity | $m | [72.5](/filings/0001193125-25-328743.md) | [62.4](/filings/0000950170-25-114224.md) | [243](/filings/0000950170-25-114224.md) | [230](/filings/0000950170-25-114224.md) | [273](/filings/0001193125-26-384383.md) | [250](/filings/0001193125-26-384383.md) | [227](/filings/0001193125-26-384383.md) | [201](/filings/0001193125-26-384383.md) | [168](/filings/0001193125-26-384383.md) | [282](/filings/0001193125-26-384383.md) | [255](/filings/0001193125-26-384383.md) | [230](/filings/0001193125-26-384383.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-10-31) | Q1 FY2024 (2024-01-31) | Q2 FY2024 (2024-04-30) | Q3 FY2024 (2024-07-31) | Q4 FY2024 (2024-10-31) | Q1 FY2025 (2025-01-31) | Q2 FY2025 (2025-04-30) | Q3 FY2025 (2025-07-31) | Q4 FY2025 (2025-10-31) | Q1 FY2026 (2026-01-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(6.8) d](/filings/0000950170-24-138472.md) | [(7.4)](/filings/0000950170-25-036281.md) | [(14.2) d](/filings/0000950170-25-085143.md) | [(7.2) d](/filings/0000950170-25-114224.md) | [(19.6) d](/filings/0001193125-25-328743.md) | [(25.7)](/filings/0001193125-26-097541.md) | [(22.9) d](/filings/0001193125-26-270386.md) | [(25.6) d](/filings/0001193125-26-384383.md) | [(25.0) d](/filings/0001193125-25-328743.md) | [(28.9)](/filings/0001193125-26-097541.md) | [(30.5) d](/filings/0001193125-26-270386.md) | [(18.9) d](/filings/0001193125-26-384383.md) |
| Capital expenditure | $m | [0.1 d](/filings/0000950170-24-138472.md) | [0.5](/filings/0000950170-25-036281.md) | [0.2 d](/filings/0000950170-25-085143.md) | [0.0 d](/filings/0000950170-25-114224.md) | [0.2 d](/filings/0001193125-25-328743.md) | [0.3](/filings/0001193125-26-097541.md) | [0.0 d](/filings/0001193125-26-270386.md) | [0.7 d](/filings/0001193125-26-384383.md) | [0.4 d](/filings/0001193125-25-328743.md) | [0.2](/filings/0001193125-26-097541.md) | [0.1 d](/filings/0001193125-26-270386.md) | [0.0 d](/filings/0001193125-26-384383.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2023-01-31) | period not labelled (2023-04-30) | period not labelled (2023-07-31) | Q1 FY2024 (2024-01-31) | Q2 FY2024 (2024-04-30) | Q3 FY2024 (2024-07-31) | Q1 FY2025 (2025-01-31) | Q2 FY2025 (2025-04-30) | Q3 FY2025 (2025-07-31) | Q1 FY2026 (2026-01-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [0.7](/filings/0000950170-24-029413.md) | [0.7](/filings/0000950170-24-073330.md) | [0.7](/filings/0000950170-24-105180.md) | [23.2](/filings/0000950170-25-036281.md) | [39.4](/filings/0000950170-25-085143.md) | [44.2](/filings/0000950170-25-114224.md) | [51.0](/filings/0001193125-26-097541.md) | [51.0](/filings/0001193125-26-270386.md) | [51.1](/filings/0001193125-26-384383.md) | [67.3](/filings/0001193125-26-097541.md) | [69.7](/filings/0001193125-26-270386.md) | [69.7](/filings/0001193125-26-384383.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 67,016,316 at 2026-09-02, from the cover of the [10-Q filed 2026-09-08](/filings/0001193125-26-384383.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.